

Day : Sunday  
Date: 7/16/2006

Time: 06:05:36

**PALM INTRANET**

# Continuity Information for 10/600098

**Parent Data**10600098is a division of 09447966Which Claims Priority from Provisional Application 60121730Which Claims Priority from Provisional Application 60146564**Child Data**10892882 is a continuation in part of 0999295711437933 is a continuation in part of 09992957PCT/US03/22817 is a continuation of 10600098

Appln Info.	Contents	Petition Info	Atty/Agent Info	Continuity/Reexam	Foreign Data
-------------	----------	---------------	-----------------	-------------------	--------------

Search Another: Application#   or Patent#    
PCT /  /   or PG PUBS #    
Attorney Docket #    
Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Day : Sunday  
 Date: 7/16/2006

Time: 06:06:29

**PALM INTRANET****Inventor Information for 10/600098**

Inventor Name	City	State/Country
MONAHAN, SEAN D.	MADISON	WISCONSIN
WOLFF, JON A.	MADISON	WISCONSIN
SLATTUM, PAUL M.	MADISON	WISCONSIN
HAGSTROM, JAMES E.	MIDDLETON	WISCONSIN
BUDKER, VLADIMIR G.	MIDDLETON	WISCONSIN
ROZEMA, DAVID B.	MADISON	WISCONSIN

[Appn Info](#) [Contents](#) [Petition Info](#) [Atty/Agent Info](#) [Continuity/Reexam](#) [Foreign](#)

Search Another: Application#   or Patent#    
 PCT /  /   or PG PUBS #    
 Attorney Docket #    
 Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

31) In another preferred embodiment, the permeability of the vessel is increased. Efficiency of polynucleotide delivery and expression was increased by increasing the permeability of a blood vessel within the target tissue.

Permeability is defined here as the propensity for macromolecules such as polynucleotides to move through vessel walls and enter the extravascular space.

One measure of permeability is the rate at which macromolecules move through the vessel wall and out of the vessel. Another measure of permeability is the lack of force that resists the movement of polynucleotides being delivered to leave the intravascular space.

only cation  
new matter?

notes for  
1098

COMPLETE LISTING OF THE CLAIMS

1-12. (canceled)

*a*

*in vivo*

13. (withdrawn) A process for analyzing gene function comprising: a) injecting a naked polynucleotide encoding the gene into a blood vessel lumen, *in vivo*; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked polynucleotide to an extravascular cell outside of the blood vessel, and d) analyzing the gene function.

14. (withdrawn) The process of claim [[1]] 13 wherein the polynucleotide consists of a gene.

15. (withdrawn) The process of claim [[1]] 13 wherein the gene encodes a protein.

16. (currently amended) A process for analyzing gene function comprising: a) injecting a naked oligonucleotide that is not expressed into a blood vessel lumen, *in vivo*; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked oligonucleotide to an extravascular cell outside of the blood vessel via the increased permeability, *and analyzing the gene function*

17. (withdrawn) The process of claim [[4]] 16 wherein the oligonucleotide consists of a single strand oligonucleotide.

18. (withdrawn) The process of claim [[5]] 17 wherein the single strand oligonucleotide consists of anti-sense oligonucleotide.

19. (withdrawn) The process of claim [[6]] 18 wherein the single strand anti-sense oligonucleotide consists of an artificial oligonucleotide.

20. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of double strand nucleic acid.

21. (currently amended) The process of claim [[8]] 20 wherein the double strand oligonucleotide comprises RNA.

22. (currently amended) The process of claim [[4]] 16 wherein delivery of the oligonucleotide to the cell results in decreased expression of the gene.

23. (currently amended) The process of claim [[9]] 21 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 10 to 50 bases.

24. (currently amended) The process of claim [[11]] 23 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 18 to 25 bases.

25. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide comprises sequence that is similar to a portion of the gene sequence.
26. (currently amended) The process of claim [[10]] 22 wherein the gene is an endogenous gene.
27. (currently amended) The process of claim [[15]] 22 wherein the gene is a viral gene.
28. (withdrawn) The process of claim [[1]] 13 wherein analyzing gene function comprises drug design.
29. (withdrawn) The process of claim [[4]] 16 wherein analyzing gene function comprises drug design.